BenevolentAI Investor Presentation Deck
1H 2022 Financial highlights
Revenue
R&D - Drug discovery ["DD"]¹
R&D - Product & technology ["P&T"]¹
G&A - Business operations ["Bus Ops"]¹
Underlying expenses related to share-based payments
Other income
Normalised operating loss
Normalised EPS (in pence)²
Weighted average ordinary shares outstanding (in millions)
Six months ended 30 June
2022
£'000
4,843
(19,292)
(10,684)
(8,074)
(22,145)
72
(55,280)
(44.7)
100.5
2021
£'000
1,664
(12,957)
(9,940)
(7,000)
(18,343)
74
(46,502)
(45.8)
89.8
1) Excludes exceptional costs related to the Business Combination
2) Normalised EPS also excludes taxation impact from exceptional items and finance income related to the Business Combination
Revenue increase across
AstraZeneca collaboration, with a
milestone reached related to the
second novel target for idiopathic
pulmonary fibrosis.
DD spend increase driven by
portfolio advancing into later stages
of development, in particular
BEN-2293 entering adaptive Phase
I/II clinical study.
P&T spend increase reflecting
increased headcount, which is set to
plateau.
Bus Ops spend +15%, driven
predominantly by listing status but
expected to maintain at this level.
Benevolent 17View entire presentation